Treatment Intensification Arms
Cross-source consensus on Treatment Intensification Arms from 1 sources and 5 claims.
1 sources · 5 claims
Uses
How it works
Dosage & preparation
Risks & contraindications
Highlighted claims
- After SCRT, patients receive one of three intensification strategies depending on centre capability: CXB boost, MR-guided EBRT boost, or CAPOX chemotherapy. — Can we Save the rectum by watchful waiting or transanal microsurgery following shorT-course radiotherapy and Additional local oR systemic Treatment for early-stage REctal Cancer? STARTREC-3 protocol for a non-randomised, multicentre, phase II platform study
- Local excision is available only in Arm 3 for small remnants after chemotherapy and is excluded from boost arms because additional local radiation increases morbidity risk from later endoluminal surgery. — Can we Save the rectum by watchful waiting or transanal microsurgery following shorT-course radiotherapy and Additional local oR systemic Treatment for early-stage REctal Cancer? STARTREC-3 protocol for a non-randomised, multicentre, phase II platform study
- CXB delivers a high-dose intraluminal radiation boost directly to the tumour with limited exposure to surrounding structures. — Can we Save the rectum by watchful waiting or transanal microsurgery following shorT-course radiotherapy and Additional local oR systemic Treatment for early-stage REctal Cancer? STARTREC-3 protocol for a non-randomised, multicentre, phase II platform study
- MR-guided radiotherapy enables precise, response-adaptive dose escalation. — Can we Save the rectum by watchful waiting or transanal microsurgery following shorT-course radiotherapy and Additional local oR systemic Treatment for early-stage REctal Cancer? STARTREC-3 protocol for a non-randomised, multicentre, phase II platform study
- CAPOX was limited to three cycles based on evidence that reduced-cycle TNT preserved high response rates with more favourable toxicity outcomes. — Can we Save the rectum by watchful waiting or transanal microsurgery following shorT-course radiotherapy and Additional local oR systemic Treatment for early-stage REctal Cancer? STARTREC-3 protocol for a non-randomised, multicentre, phase II platform study